47 search results for: comorbidities
Type 2 Inflammation in AD Manifestations in Skin and Body
Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.
Bullous Pemphigoid (BP): Don't Miss the Diagnosis
This static infographic covers the clinical presentations, diagnostic challenges, and disease burden of bullous pemphigoid (BP), a chronic relapsing autoimmune skin disease. Review the steps of diagnosis, which include clinical assessment and laboratory work. Explore comorbidities associated with BP and how they impact patient quality of life.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
ADVENT On Air Podcast: Unmet Needs and Current Treatment Landscape
In this podcast, Dr. Teri Greiling and Dr. Daniel Butler discuss the enormous burden patients with bullous pemphigoid experience and how our understanding of the disease pathophysiology may help address unmet treatment needs.
Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention
Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively.
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis
Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.
Impact of Advanced Systemic Therapies on Disease Control in AD
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
Lung Function Decline: Why it Matters and What’s at Stake for Patients
Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .
The Role of Type 2 Inflammation in Multiple Disease Trajectories
How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.
